CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma
Diffuse large B-cell lymphoma (DLBCL) exhibits significant genetic heterogeneity which contributes to drug resistance, necessitating development of novel therapeutic approaches. Pharmacological inhibitors of c...
Source: Molecular Cancer - Category: Cancer & Oncology Authors: Elana Thieme, Nur Bruss, Duanchen Sun, Edward C. Dominguez, Daniel Coleman, Tingting Liu, Carly Roleder, Melissa Martinez, Krystine Garcia-Mansfield, Brian Ball, Patrick Pirrotte, Lili Wang, Zheng Xia and Alexey V. Danilov Tags: Research Source Type: research